Group 2 PH: Medical Therapy

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary hypertension (PH) from left heart disease (Group 2 PH) is often overlooked in early stages.
• Focus is typically on advanced heart failure (HF) patients, but interest is growing in elderly populations and HF with preserved ejection fraction (HFpEF).
• Effective treatments for earlier stages of Group 2 PH, especially in HFpEF, remain a challenge.

Purpose of the Study:

• To review the current understanding and therapeutic approaches for pulmonary hypertension secondary to left heart disease.
• To explore the potential of targeting the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway for earlier intervention.
• To assess the safety and efficacy of novel pharmacological agents in managing this condition.

Main Methods:

• Review of existing literature on Group 2 PH, its clinical significance, and therapeutic strategies.
• Analysis of pharmacological studies, including traditional pulmonary arterial hypertension drugs and newer agents targeting the NO-cGMP pathway.
• Evaluation of safety profiles, hemodynamic results, and tolerability of investigated treatments.

Main Results:

• Traditional pulmonary arterial hypertension drugs have shown limited success and significant side effects in Group 2 PH.
• Newer drugs, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators, demonstrate good tolerability and safety.
• Hemodynamic results with NO-cGMP pathway drugs are variable, potentially due to patient heterogeneity in disease stages.

Conclusions:

• The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway represents a promising target for managing lung microvessel and right ventricular (RV) dysfunction in early Group 2 PH.
• Selective pulmonary vasodilators targeting this pathway offer a favorable safety profile.
• Further research is needed to optimize treatment strategies and define the role of these agents in different stages of Group 2 PH, particularly in HFpEF.